FrancophonIA/ELRC3.0 huggingface dataset:
English: Use caution when driving or using machines.
Croatian: Budite oprezni prilikom upravljanja vozilima i strojevima.
English: Of the 215 subjects with sufficient data to determine mutational status, 78.6% (n=169) were classified as RET mutation positive (126 of which were positive for the M918T mutation), and 21.4% (n=46) were classified as RET mutation negative.
Croatian: Od 215 ispitanika za koje je postojalo dovoljno podataka za određivanje mutacijskog statusa, njih 78,6% (n=169) su klasificirani kao pozitivni na mutaciju RET-a (od čega je 126 ispitanika bilo pozitivno na mutaciju M918T), a 21,4% (n=46) su klasificirani kao negativni na mutaciju RET-a.
English: Your capsules are also available as a 28 day pack, which contains enough capsules to last for 28 days, in 4 blister cards with seven days of capsules on each card.
Croatian: Kapsule su vam također dostupne u pakiranju za 28 dana koje sadržava kapsule za primjenu tijekom 28 dana, raspoređene u 4 blister kartice od kojih svaka sadržava količinu kapsula koja je dovoljna za primjenu tijekom sedam dana.
English: Urine protein should be monitored regularly during cabozantinib treatment.
Croatian: Tijekom liječenja kabozantinibom mora se redovito kontrolirati proteine u urinu.
English: • Seizures, headaches, confusion, or finding it difficult to concentrate.
Croatian: • Napadaji, glavobolje, smetenost ili poteškoće s koncentriranjem.
English: There was no improvement in OS for the RET M918T negative and unknown subgroups.
Croatian: Nije bilo poboljšanja OS-a u podskupinama negativnim na mutaciju RET M918T i s nepoznatim statusom mutacije.
English: Cabozantinib should be discontinued in patients who develop an acute myocardial infarction or any other clinically significant arterial thromboembolic complication.
Croatian: Mora se prestati s primjenom kabozantiniba u bolesnika u kojih se pojavi akutni infarkt miokarda ili bilo koja druga klinički značajna arterijska tromboembolijska komplikacija.
English: Black iron oxide (E172) (20 mg capsules only) Red iron oxide (E172) (80 mg capsules only) Titanium dioxide (E171)
Croatian: Ovojnica kapsule želatina željezov oksid, crni (E172) (samo kapsule od 20 mg) željezov oksid, crveni (E172) (samo kapsule od 80 mg) titanijev dioksid (E171)
English: Olbrachtova 2006/9,
Croatian: Olbrachtova 2006/9, 140 00 Praha 4
English: Further, hypospermatogenesis was observe in male dogs at exposure levels below human clinical exposure levels at intended therapeutic dose.
Croatian: Pored toga, zabilježena je hipospermatogeneza u mužjaka pasa pri razinama ekspozicije ispod razina kliničke ekspozicije u ljudi koje odgovaraju predviđenoj terapijskoj dozi.
English: For invasive dental procedures, cabozantinib treatment should be held at least 28 days prior to scheduled surgery, if possible.
Croatian: U slučaju invazivnih stomatoloških zahvata, mora se prekinuti liječenje kabozantinibom najmanje 28 dana prije zakazane operacije, ako je moguće.
English: Effective methods of contraception should be used by male and female patients and their partners during therapy, and for at least 4 months after completing therapy.
Croatian: Muški i ženski bolesnici te njihovi partneri moraju koristiti djelotvorne metode kontracepcije tijekom terapije i najmanje 4 mjeseca nakon završetka primanja terapije.
English: In addition, cabozantinib inhibits other tyrosine kinases including RET, the GAS6 receptor (AXL), the stem cell factor receptor (KIT), and Fms-like tyrosine kinase-3 (FLT3).
Croatian: Pored toga, kabozantinib inhibira druge tirozine kinaze, uključujući RET, receptor GAS6 (AXL), receptor faktora matičnih stanica (KIT) te Fms-sličnu tirozinsku kinazu 3 (FLT3).
English: NOAEL for embryo-foetal toxicity and teratogenic findings were below human clinical exposure levels at intended therapeutic dose.
Croatian: NOAEL za embrio-fetalnu toksičnost i teratogene nalaze su bili ispod razina kliničke ekspozicije u ljudi koje odgovaraju predviđenoj terapijskoj dozi.
English: BLISTER CARD, 60 mg dose
Croatian: BLISTER KARTICA, doza od 100 mg
English: INFORMATION IN BRAILLE COMETRIQ 20 mg
Croatian: 16. PODACI NA BRAILLEOVOM PISMU COMETRIQ 20 mg
English: In the 2-year rat carcinogenicity study, cabozantinib-related neoplastic findings consisted of an increased incidence of benign pheochromocytoma, alone or in combination with malignant pheochromocytoma/complex malignant pheochromocytoma of the adrenal medulla in both sexes at exposures well below the intended exposure in humans.
Croatian: U ispitivanju kancerogenosti u štakora u trajanju od 2 godine, neoplastični nalazi povezani s kabozantinibom sastojali su se od povećane incidencije benignog feokromocitoma, samog ili u kombinaciji s malignim feokromocitomom/kompleksnim malignim feokromocitomom srži nadbubrežne žlijezde u oba spola pri izloženostima daleko nižima od predviđene izloženosti u ljudi.
English: The PFS results were consistent across all baseline and demographic subgroups evaluated, including prior therapy with tyrosine kinase inhibitors (which may have consisted of agents targeting pathways associated with anti-angiogenesis), RET mutational status (including subjects documented not to have RET mutations), prior anticancer or radiotherapy status, or the existence of bone metastases.
Croatian: PFS rezultati su se pokazali konzistentnim u svim početnim i demografskim podskupinama koje su ispitivane, uključujući ispitanike s prethodnom terapijom inhibitorima tirozinskih kinaza (koje su se mogle sastojati od agensa koji ciljaju puteve povezane s anti-angiogenezom), RET mutacijski status (uključujuči ispitanika koji dokumentirano nemaju mutacije RET-a), raniji antikancerogeni ili radioterapijski status ili postojanje metastaza u kostima.
English: Following oral administration of cabozantinib, peak cabozantinib plasma concentrations are reached at 2 to 5 hours post-dose.
Croatian: Nakon peroralne primjene kabozantiniba, vršne koncentracije kabozantiniba u plazmi su postignute od 2 do 5 sati nakon uzimanja doze.
English: If your next dose is due in less than 12 hours then do not take the dose that you have missed.
Croatian: Ako ima manje od 12 sati do iduće doze, nemojte uzimati propuštenu dozu.
English: The active substance is cabozantinib (S)-malate.
Croatian: Djelatna tvar je kabozantnib (S)-malat.
English: RET mutation negative patients with no evidence of RAS mutation (n=33) showed a decreased PFS benefit on cabozantinib (HR of 0.87) and a lower response rate of 18% compared to other mutational subgroups.
Croatian: Bolesnici negativni na mutaciju RET-a kod kojih ne postoje dokazi o mutaciji RAS-a (n=33) su pokazali smanjenu PFS korist od kabozantiniba (HR od 0,87) te niži stopu terapijskog odgovora od 18% u usporedbi s ostalim mutacijskim podskupinama.
English: A thyroid stimulating hormone (TSH) value above normal after first dose was observed in 57% of patients on cabozantinib versus 19% of patients on placebo (regardless of baseline values).
Croatian: Vrijednost tireoidnog stimulirajućeg hormona (TSH) iznad normalne vrijednosti je zabilježena nakon prve doze u 57% bolesnika na kabozantinibu, naspram 19% bolesnika na placebu (bez obzira na početne vrijednosti).
English: The no observed adverse effect level (NOAEL) for these findings were below human clinical exposure levels at intended therapeutic dose.
Croatian: Razina bez primijećenih štetnih učinaka (NOAEL) za ove rezultate je bila ispod razina kliničke ekspozicije u ljudi koje odgovaraju predviđenoj terapijskoj dozi.
English: • Abnormal hair growth
Croatian: • Abnormalan rast kose
English: RET mutation status
Croatian: Status mutacije RET-a
English: 21.1 months HR: 0.85 (0.64, 1.12) p = 0.2409
Croatian: 21,1 mjeseci HR: 0,85 (0,64; 1,12) P = 0,2409
English: What COMETRIQ looks like and contents of the pack COMETRIQ 20 mg capsules are grey and have “XL184 20mg” printed on one side.
Croatian: Kako COMETRIQ izgleda i sadržaj pakiranja COMETRIQ kapsule od 20 mg su sive boje i imaju oznaku “XL184 20mg” utisnutu s jedne strane.
English: Cabozantinib was an inhibitor (IC50 = 7.0 μM), but not a substrate, of P-glycoprotein (P-gp) transport activities in a bi-directional assay system using MDCK-MDR1 cells.
Croatian: Kabozantinib je bio inhibitor (IC50 = 7,0 μM), ali ne i supstrat, transportnih djelovanja P-glikoproteina (P-gp) u dvosmjernom sustavu testa uz uporabu MDCK-MDR1 stanica.
English: Figure 3: Kaplan-Meier Analysis of OS Among Subjects with a RET M918T Mutation
Croatian: Slika 3: Kaplan-Meierova analiza ukupnog preživljenja u ispitanika s mutacijom RET M918T
English: • A condition called posterior reversible encephalopathy syndrome (PRES) or reversible posterior leukoencephalopathy syndrome (RPLS), which has symptoms such as seizures, headaches,
Croatian: • Stanje koje se naziva sindrom posteriorne reverzibilne encefalopatije (PRES) ili sindrom reverzibilne posteriorne leukoencefalopatije (RPLS) čiji simptomi uključuju napadaje,
English: The final analysis of OS was conducted after 218 events (deaths) occurred and shows a trend for an increase in median survival of 5.5 months in the cabozantinib arm: median (months) 26.6 cabozantinib vs. 21.1 placebo (HR = 0.85 [95% CI: 0.64, 1.12], p = 0.2409).
Croatian: Konačna analiza OS-a provedena je nakon 218 događaja (smrtnih slučajeva) i pokazuje tendenciju povećanja medijana preživljenja od 5,5 mjeseci u kabozantinib skupini: medijan (mjeseci) 26,6 za kabozantinib naspram 21,1 za placebo (HR = 0,85 [95% CI: 0,64; 1,12], p = 0,2409).
English: Dispensing instructions
Croatian: Upute za uzimanje
English: Median Progression-Free Survival
Croatian: Medijan preživljenja bez progresije bolesti
English: In rat and dog repeat-dose toxicity studies up to 6 months duration, target organs for toxicity were GI tract, bone marrow, lymphoid tissues, kidney, adrenal and reproductive tract tissues.
Croatian: Ispitivanja toksičnosti ponavljajućih doza u štakora i pasa u trajanju do 6 mjeseci, ciljni organi za toksičnost su bili gastrointestinalni trakt, koštana srž, limfatično tkivo, bubreg te nadbubrežno tkivo i tkivo reproduktivnog trakta.
English: All three subgroups showed increased PFS in the cabozantinib arm compared to the placebo arm (HRs of 0.23, 0.53, and 0.30 for RET mutation positive, negative, and unknown subgroups, respectively).
Croatian: Sve tri podskupine su pokazale povećan PFS u kabozantinib skupini u usporedbi s placebo skupinom (HR od 0,23; 0,53 i 0,30 za skupine pozitivne na mutaciju RET-a, odnosno negativne, odnosno nepoznate).
English: Juvenile rats (comparable to a >2 year old pediatric population) administered cabozantinib showed increased WBC parameters, decreased haematopoiesis, pubescent/immature female reproductive system (without delayed vaginal opening), tooth abnormalities, reduced bone mineral content and density, liver pigmentation and bile duct hyperplasia.
Croatian: U mladih štakora (koji su usporedivi s pedijatrijskom populacijom starosti >2 godine) u kojih je primijenjen kabozantinib došlo je do povećanja parametara leukocita, smanjenja hematopoeze, pubescentnog/nezrelog ženskog spolnog sustava (bez odgođenog vaginalnog otvaranja), abnormalnosti zuba, smanjenog mineralnog sadržaja i gustoće kostiju, pigmentacije jetre i hiperplazije žučovoda.
English: NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER Ipsen Pharma
Croatian: 11. NAZIV I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET Ipsen Pharma
English: Cabozantinib exhibited dose-related tumour growth inhibition, tumor regression, and/or inhibited metastasis in a broad range of preclinical tumour models.
Croatian: Kabozantinib je pokazao inhibiciju rasta tumora ovisnu o dozi, utjecao na regresiju tumora i/ili inhibirao metastaze u širokom spektru prekliničkih modela tumora.
English: Repeat daily dosing of cabozantinib at 140 mg for 19 days resulted in an approximately a 4- to 5-fold mean cabozantinib accumulation (based on AUC) compared to a single dose administration; steady state is achieved by approximately Day 15.
Croatian: Ponavljanje dnevne doze kabozantiniba od 140 mg tijekom 19 dana rezultiralo je otprilike četverostruko do peterostruko većom srednjom vrijednosti akumulacije kabozantiniba (na osnovu AUC) u usporedbi s primjenom jedne doze; stanje dinamičke ravnoteže je postignuto otprilike 15.og dana.
English: • Protein or blood in the urine, gallstones, painful urination
Croatian: • Proteini ili krv u mokraći, žučni kamenci, bolno mokrenje
English: Clinical data in medullary thyroid cancer
Croatian: Klinički podaci u bolesnika s medularnim rakom štitnjače
English: • Inflammation of the lips and corners of the mouth
Croatian: • Upala usnica i rubova usta
English: Non-GI fistula should be ruled out as appropriate in cases of onset of mucositis after start of therapy.
Croatian: Fistule izvan gastrointestinalnog sustava se moraju isključiti u slučaju pojave mukozitisa nakon početka terapije.
English: An oral examination should be performed prior to initiation of cabozantinib and periodically during cabozantinib therapy.
Croatian: Prije početka primjene kabozantiniba mora se napraviti oralni pregled te potom periodično tijekom terapije kabozantinibom.
English: Therefore chronic administration of agents that are strong CYP3A4 inducers with cabozantinib should be avoided (see sections 4.2 and 4.5).
Croatian: Prema tome, mora se izbjegavati kroničnu primjenu lijekova koji spadaju u jake induktore CYP3A4 s kabozantinibom (vidjeti dijelove 4.2 i 4.5).
English: A significant improvement in OS was observed in the subgroup of RET M918T mutation positive patients (n=81/219 cabozantinib arm): 44.3 months in the cabozantinib arm vs. 18.9 months in the placebo arm (HR = 0.60, p = 0.0255).
Croatian: Značajno poboljšanje ukupnog preživljenja primijećeno je u podskupini bolesnika koji su bili pozitivni na mutaciju RET M918T (n=81/219 u kabozantinib skupini): 44,3 mjeseca u kabozantinib skupini naspram 18,9 mjeseci u placebo skupini (HR = 0,60, p = 0,0255).
English: Take the next dose at the normal time.
Croatian: Iduću dozu uzmite u predviđeno vrijeme.
English: Patients with both sporadic and hereditary forms of MTC will be eligible for the study.
Croatian: Bolesnici koji imaju i sporadični i nasljedni oblik medularnog karcinoma štitnjače će biti podobni za ispitivanje.
English: Patients who have evidence of involvement of the trachea or bronchi by tumour or a history of haemoptysis prior to treatment initiation should be carefully evaluated before initiating cabozantinib therapy.
Croatian: U bolesnika u kojih postoji dokaz o tumoru koji obuhvaća dušnik ili bronhe ili koji imaju anamnezu hemoptize mora se napraviti pažljiva procjena prije početka liječenja kabozantinibom.
English: A high-fat meal moderately increased Cmax and AUC values (41% and 57%, respectively) relative to fasted conditions in healthy volunteers administered a single 140 mg oral cabozantinib dose.
Croatian: Obrok s visokom količinom masti je umjereno povećao Cmax i AUC vrijednosti (41%, odnosno 57%) u odnosu na stanje natašte u zdravih dobrovoljaca kad se primjenjuje jedna peroralna doza kabozantiniba od 140 mg.
English: aspergilloma
Croatian: aspergilom
English: Efficacy with cabozantinib was observed in medullary thyroid cancer patients with wild-type or mutant RET.
Croatian: Djelotvornost kabozantiniba je zabilježena u bolesnika koji boluju od medularnog raka štitnjače s RET-om divljeg tipa ili mutiranim.
English: • Fatigue, weakness, headache, dizziness
Croatian: • Umor, slabost, glavobolja, omaglica
English: The result of the PFS analysis, based on the central review RECIST assessment, demonstrated a statistically significant difference in the duration of PFS with cabozantinib versus placebo: the median duration was 11.2 months for subjects in the cabozantinib arm versus 4.0 months for subjects in the placebo arm (stratified Hazard Ratio [HR] = 0.28; 95% CI: 0.19, 0.40; p<0.0001; Figure 1).
Croatian: Rezultati PFS analize, temeljeni na centralnoj procjeni RECIST-a, su pokazali statistički značajnu razliku u trajanju PFS-a s kabozantinibom naspram placeba: medijan je bio 11,2 mjeseca u skupini ispitanika kod kojih je primjenjivan kabozantinib nasuprot 4,0 mjeseca u skupini ispitanika kod kojih je primjenjivan placebo (stratificirani omjer rizika [HR] = 0,28; 95% CI: 0,19, 0,40; p<0,0001; Slika 1).
English: Ear and labyrinth disorders ear pain, tinnitus hypoacusis
Croatian: Poremećaji uha i labirinta bol u uhu, tinitus hipoakuzija
English: Concomitant treatment with strong CYP3A4 inhibitors, which may increase cabozantinib plasma concentrations, should be used with caution.
Croatian: Istodobno liječenje lijekovima koji spadaju u skupinu jakih inhibitora CYP3A4, koji mogu povećati koncentracije kabozantiniba u plazmi, mora se primjenjivati s oprezom.
English: • Infection and inflammation in the lung, collapse of lung
Croatian: • Infekcija i upala pluća, kolaps pluća
English: Cabozantinib treatment should be discontinued in patients with RPLS.
Croatian: Mora se prekinuti liječenje s kabozantinibom u bolesnika s RPLS-om.
English: The most common laboratory abnormalities were increased aspartate aminotransferase (AST), increased alanine aminotransferase (ALT), increased alkaline phosphatase (ALP), lymphopenia, hypocalcaemia, neutropenia, thrombocytopenia, hypophosphataemia, hyperbilirubinemia, hypomagnesaemia, and hypokalaemia.
Croatian: Najčešći laboratorijski poremećaji bili su povećanje aspartat aminotransferaze (AST), povećanje alanin aminotransferaze (ALT), povećanje alkalne fosfataze (ALP), limfopenija, hipokalcemija, neutropenija, trombocitopenija, hipofosfatemija, hiperbilirubinemija, hipomagnezemija i hipokalemija.
English: There are no studies in pregnant women using cabozantinib.
Croatian: Nisu provedena ispitivanja s primjenom kabozantiniba u trudnica.
English: Metabolism and nutrition disorders decreased appetite, hypocalcaemia, hypophosphataemia, hyperbilirubinemia, hypokalaemia, hypomagnesaemia dehydration, hypoalbuminaemia
Croatian: Poremećaji metabolizma i prehrane smanjen apetit, hipokalcemija, hipofosfatemija, hiperbilirubinemija, hipokalemija, hipomagnezemija dehidracija, hipoalbuminemija
English: In patients with mild or moderate hepatic impairment the recommended dose of cabozantinib is 60 mg once daily.
Croatian: Preporučena doza kabozantiniba u bolesnika s blagim ili umjerenim oštećenjem funkcije jetre iznosi 60 mg jedanput dnevno.
English: COMETRIQ 80 mg capsules are orange and have “XL184 80mg” printed on one side.
Croatian: COMETRIQ kapsule od 80 mg su narančaste boje i imaju oznaku “XL184 80mg” utisnutu s jedne strane.
English: • Tear or hole or bleeding in your stomach or intestine, inflammation or tear of anus, , bleeding in lungs or trachea (airway)
Croatian: • Razdor, rupa ili krvarenje u želucu ili crijevima, upala ili razdor anusa, krvarenje u plućima ili dušniku (dišnim putovima)
English: Caution is required when administering cabozantinib with agents that are strong CYP3A4 inhibitors.
Croatian: Potreban je oprez prilikom primjene kabozantiniba s lijekovima koji spadaju u jake inhibitore CYP3A4.
English: Patients who have had recent radiotherapy, have inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, peritonitis, or diverticulitis), have tumour infiltration of trachea, bronchi, or oesophagus, have complications from prior GI surgery (particularly when associated with delayed or incomplete healing), or have complications from prior radiation therapy to the thoracic cavity (including mediastinum) should be carefully evaluated before initiating cabozantinib therapy and subsequently they should be monitored closely for symptoms of perforations and fistulas.
Croatian: U bolesnika koji su u skorije vrijeme bili podvrgnuti radioterapiji, imaju upalnu bolest crijeva (npr. Crohnovu bolest, ulcerozni kolitis, peritonitis ili divertikulitis), imaju infiltraciju dušnika, bronha ili jednjaka tumorom, koji su pretrpjeli komplikacije od prethodne gastrointestinalne operacije (naročito komplikacije koje su povezane s usporenim ili nepotpunim cijeljenjem) ili imaju komplikacije od prethodne radioterapije prsnog koša (uključujući medijastinum) mora se napraviti pažljiva procjena prije početka terapije kabozantinibom te slijedom navedenog njih se mora pažljivo pratiti hoće li se pojaviti simptomi perforacija i fistula.
English: Reversible Posterior Leukoencephalopathy Syndrome (RPLS), also known as Posterior Reversible Encephalopathy Syndrome (PRES) has been observed with cabozantinib.
Croatian: Sindrom reverzibilne posteriorne leukoencefalopatije Prilikom primjene kabozantiniba zabilježen je sindrom reverzibilne posteriorne leukoencefalopatije (RPLS), također poznat kao sindrom posteriorne reverzibilne encefalopatije (PRES).
English: Events that generally have early onset include hypocalcaemia, hypokalaemia, thrombocytopenia, hypertension, palmarplantar erythrodysaesthesia syndrome (PPES), and gastrointestinal (GI) events (abdominal or mouth pain, mucosal inflammation, constipation, diarrhoea, vomiting).
Croatian: Događaji koji se većinom javljaju rano uključuju hipokalcemiju, hipokalemiju, trombocitopeniju, hipertenziju, sindrom palmarno-plantarne eritrodizestezije (PPES) i gastrointestinalne (GI) događaje (bol u abdomenu ili ustima, upala sluznice, konstipacija, proljev, povraćanje).
English: The most frequent adverse reactions of any grade (experienced by at least 20% of patients) included diarrhoea, PPES, weight decreased, decreased appetite, nausea, fatigue, dysgeusia, hair colour changes, hypertension, stomatitis, constipation, vomiting, mucosal inflammation, asthenia, and dysphonia.
Croatian: Najčešće nuspojave bilo kojeg stupnja (nuspojave koje su se javile u najmanje 20% bolesnika) uključuju proljev, PPES, gubitak na tjelesnoj težini, smanjen apetit, mučninu, umor, disgeuziju, promjenu boje kose, hipertenziju, stomatitis, konstipaciju, povraćanje, upalu sluznice, asteniju i disfoniju.
English: Results from a study in patients with hepatic impairment indicate that exposure (AUC0-inf) increased by 81% and 63% in subjects with mild and moderate hepatic impairment, respectively (90% CI for AUC0-inf: 121.44% to 270.34% for mild and 107.37% to 246.67% for moderate).
Croatian: Rezultati ispitivanja kod bolesnika s oštećenom funkcijom jetre ukazuju na to da se izloženost (AUC0-inf) povećala za 81 % i 63 % u ispitanika s blagim, odnosno umjerenim oštećenjem funkcije jetre (90% CI za AUC0-inf: 121,44 % do 270,34 % za blago i 107,37 % do 246,67 % za umjereno oštećenje).
English: In rabbits, cabozantinib produced foetal soft tissue changes (reduced spleen size, small or missing intermediate lung lobe) and increased foetal incidence of total malformations.
Croatian: U kunića je kabozantinib uzrokovao promjene u mekom tkivu fetusa (smanjena veličina slezene, smanjenje ili gubitak srednjeg plućnog krila) te povećanu incidenciju ukupnih deformacija u fetusa.
English: • Generalised pain, chest or muscle pain, ear pain, ringing in ears
Croatian: • Opća bol, bol u prsima ili mišićima, bol u uhu, zvonjenje u ušima
English: Cabozantinib was evaluated for its inhibitory activity against a variety of kinases and was identified as an inhibitor of MET (hepatocyte growth factor receptor protein) and VEGF (vascular endothelial growth factor) receptors.
Croatian: Ispitivano je inhibitorsko djelovanje kabozantiniba na razne kinaze te se ustanovilo da je kabozantinib inhibitor MET (receptor faktora rasta hepatocita) i VEGF (krvožilni endotelni faktor rasta) receptora.
English: Concomitant medicinal products that are strong inhibitors of CYP3A4 should be used with caution, and chronic use of concomitant medicinal products that are strong inducers of CYP3A4 should be avoided (see sections 4.4 and 4.5).
Croatian: Lijekove koji se uzimaju istodobno, a spadaju u skupinu jakih inhibitora CYP3A4 mora se koristiti s oprezom, a kroničnu primjenu lijekova koji se uzimaju istodobno, a spadaju u skupinu jakih induktora CYP3A4 mora se izbjegavati (vidjeti dijelove 4.4 i 4.5).